Healthcare companies by risk reading
Healthcare companies by risk reading: 1,214 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 1 September 2026.
Composite readings for 8,308 companies, recomputed 1 September 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Solventum Corp SOLV | 49 | Elevated | Healthcare | United States | 5 / 6 | $15.5B |
| BridgeBio Pharma Inc BBIO | 45 | Elevated | Healthcare | United States | 5 / 6 | $15.0B |
| JD HEALTH INTL LTD 8ZN | 41 | Elevated | Healthcare | China | 5 / 6 | $14.8B |
| Eurofins Scientific SE ERF | 46 | Elevated | Healthcare | Luxembourg | 5 / 6 | $14.5B |
| Revvity Inc RVTY | 51 | Elevated | Healthcare | United States | 5 / 6 | $14.4B |
| CSPC Pharmaceutical Group Limited 1093.HK | 44 | Elevated | Healthcare | Hong Kong | 5 / 6 | $13.9B |
| Charles River Laboratories International Inc CRL | 56 | Elevated | Healthcare | United States | 4 / 6 | $13.8B |
| Cooper Companies Inc COO | 44 | Elevated | Healthcare | United States | 5 / 6 | $13.7B |
| Exelixis Inc EXEL | 18 | Contained | Healthcare | United States | 4 / 6 | $13.6B |
| Pro Medicus Ltd. PMC | 9 | Contained | Healthcare | Australia | 4 / 6 | $13.5B |
| Baxter International Inc BAX | 61 | Stretched | Healthcare | United States | 5 / 6 | $13.4B |
| Icon Plc ICLR | 56 | Elevated | Healthcare | Ireland | 4 / 6 | $12.7B |
| Penumbra Inc PEN | 33 | Normal | Healthcare | United States | 4 / 6 | $12.7B |
| Biomarin Pharmaceutical Inc BMRN | 30 | Normal | Healthcare | United States | 5 / 6 | $12.6B |
| Madrigal Pharmaceuticals Inc MDGL | 73 | Stretched | Healthcare | United States | 4 / 6 | $12.5B |
| Smith & Nephew plc SNN | 46 | Elevated | Healthcare | United Kingdom | 5 / 6 | $12.2B |
| Corcept Therapeutics Inc CORT | 39 | Normal | Healthcare | United States | 5 / 6 | $12.2B |
| CSPC PHARMACEUT.GR. ADR4 CVGU | 45 | Elevated | Healthcare | China | 5 / 6 | $12.2B |
| Halozyme Therapeutics Inc HALO | 22 | Normal | Healthcare | United States | 4 / 6 | $12.1B |
| Fresenius Medical Care AG & Co. KGaA FMS | 51 | Elevated | Healthcare | Germany | 5 / 6 | $12.1B |
| Elanco Animal Health Inc ELAN | 60 | Stretched | Healthcare | United States | 4 / 6 | $11.9B |
| Encompass Health Corp EHC | 33 | Normal | Healthcare | United States | 4 / 6 | $11.9B |
| Arrowhead Pharmaceuticals Inc ARWR | 19 | Contained | Healthcare | United States | 5 / 6 | $11.6B |
| BrightSpring Health Services Inc BTSG | 38 | Normal | Healthcare | United States | 5 / 6 | $11.5B |
| Align Technology Inc ALGN | 46 | Elevated | Healthcare | United States | 5 / 6 | $11.4B |
| Tempus AI Inc - Class A TEM | 66 | Stretched | Healthcare | United States | 4 / 6 | $11.4B |
| Bio-Techne Corp TECH | 34 | Normal | Healthcare | United States | 5 / 6 | $11.3B |
| WuXi XDC Cayman Inc. L74 | 23 | Normal | Healthcare | China | 5 / 6 | $11.3B |
| AKESO INC. O.N. 4RY | 49 | Elevated | Healthcare | China | 5 / 6 | $11.1B |
| Globus Medical Inc - Class A GMED | 27 | Normal | Healthcare | United States | 5 / 6 | $10.9B |
| Krystal Biotech Inc KRYS | 19 | Contained | Healthcare | United States | 4 / 6 | $10.6B |
| Glaukos Corporation GKOS | 63 | Stretched | Healthcare | United States | 4 / 6 | $10.6B |
| DaVita Inc DVA | 44 | Elevated | Healthcare | United States | 5 / 6 | $10.3B |
| Bio-Rad Laboratories Inc - Class A BIO | 57 | Elevated | Healthcare | United States | 5 / 6 | $10.3B |
| Universal Health Services Inc - Class B UHS | 39 | Normal | Healthcare | United States | 5 / 6 | $10.3B |
| Insulet Corporation PODD | 27 | Normal | Healthcare | United States | 5 / 6 | $10.3B |
| Henry Schein Inc HSIC | 47 | Elevated | Healthcare | United States | 5 / 6 | $10.2B |
| Axsome Therapeutics Inc AXSM | 37 | Normal | Healthcare | United States | 5 / 6 | $10.2B |
| Repligen Corp RGEN | 46 | Elevated | Healthcare | United States | 5 / 6 | $10.2B |
| Dr. Reddy`s Laboratories Ltd RDY | 47 | Elevated | Healthcare | India | 5 / 6 | $10.1B |
| Ensign Group Inc ENSG | 33 | Normal | Healthcare | United States | 5 / 6 | $10.0B |
| Ionis Pharmaceuticals Inc IONS | 51 | Elevated | Healthcare | United States | 5 / 6 | $10.0B |
| bioMérieux S.A EYWN | 41 | Elevated | Healthcare | France | 5 / 6 | $10.0B |
| Cytokinetics Inc CYTK | 65 | Stretched | Healthcare | United States | 5 / 6 | $9.8B |
| Avantor Inc AVTR | 70 | Stretched | Healthcare | United States | 4 / 6 | $9.8B |
| Kymera Therapeutics Inc KYMR | 72 | Stretched | Healthcare | United States | 5 / 6 | $9.8B |
| Protagonist Therapeutics Inc PTGX | 36 | Normal | Healthcare | United States | 5 / 6 | $9.6B |
| Genscript Biotech Corporation G51 | 33 | Normal | Healthcare | Hong Kong | 5 / 6 | $9.5B |
| Masimo Corp MASI | 38 | Normal | Healthcare | United States | 5 / 6 | $9.4B |
| Demant A/S DEMANT | 45 | Elevated | Healthcare | Denmark | 5 / 6 | $9.3B |
| Crinetics Pharmaceuticals Inc CRNX | 45 | Elevated | Healthcare | United States | 5 / 6 | $9.0B |
| Qiagen NV QGEN | 36 | Normal | Healthcare | Netherlands | 5 / 6 | $8.9B |
| Bruker Corp BRKR | 58 | Elevated | Healthcare | United States | 5 / 6 | $8.8B |
| Twist Bioscience Corp TWST | 40 | Elevated | Healthcare | United States | 5 / 6 | $8.7B |
| Aptargroup Inc ATR | 45 | Elevated | Healthcare | United States | 4 / 6 | $8.4B |
| ImmunityBio Inc IBRX | 41 | Elevated | Healthcare | United States | 5 / 6 | $8.3B |
| TG Therapeutics Inc TGTX | 25 | Normal | Healthcare | United States | 5 / 6 | $8.3B |
| 10x Genomics Inc - Class A TXG | 50 | Elevated | Healthcare | United States | 4 / 6 | $8.1B |
| Healthequity Inc HQY | 25 | Normal | Healthcare | United States | 4 / 6 | $8.1B |
| Bio-Rad Laboratories Inc - Class B BIO-B | 56 | Elevated | Healthcare | United States | 5 / 6 | $8.0B |
| Alkermes plc ALKS | 31 | Normal | Healthcare | Ireland | 5 / 6 | $7.9B |
| Grifols S.A OZTA | 37 | Normal | Healthcare | Spain | 4 / 6 | $7.7B |
| M3 INC. 4YC | 31 | Normal | Healthcare | Japan | 4 / 6 | $7.6B |
| Sonic Healthcare Limited SAB | 53 | Elevated | Healthcare | Australia | 4 / 6 | $7.6B |
| ALK-Abelló A/S ALK-B | 28 | Normal | Healthcare | Denmark | 4 / 6 | $7.4B |
| Hinge Health Inc - Class A HNGE | 56 | Elevated | Healthcare | United States | 5 / 6 | $7.4B |
| Ramsay Health Care Ltd RHC | 49 | Elevated | Healthcare | Australia | 4 / 6 | $7.3B |
| Rhythm Pharmaceuticals Inc RYTM | 44 | Elevated | Healthcare | United States | 5 / 6 | $7.3B |
| Caris Life Sciences Inc - Class A CAI | 30 | Normal | Healthcare | United States | 5 / 6 | $7.2B |
| Bachem Holding AG BANB | 45 | Elevated | Healthcare | Switzerland | 4 / 6 | $7.2B |
| Getinge AB ser. B GETI-B | 53 | Elevated | Healthcare | Sweden | 3 / 6 | $7.0B |
| Sysmex Corporation 0YX | 49 | Elevated | Healthcare | Japan | 5 / 6 | $7.0B |
| Cidara Therapeutics Inc CDTX | 68 | Stretched | Healthcare | United States | 5 / 6 | $7.0B |
| Hims & Hers Health Inc - Class A HIMS | 51 | Elevated | Healthcare | United States | 4 / 6 | $6.8B |
| Chemed Corp CHE | 23 | Normal | Healthcare | United States | 5 / 6 | $6.8B |
| Arcellx Inc ACLX | 60 | Stretched | Healthcare | United States | 5 / 6 | $6.7B |
| PACS Group Inc PACS | 32 | Normal | Healthcare | United States | 5 / 6 | $6.7B |
| ASAHI INTECC CO. LTD. 6XT | 25 | Normal | Healthcare | Japan | 5 / 6 | $6.6B |
| Cg Oncology Inc CGON | 34 | Normal | Healthcare | United States | 5 / 6 | $6.6B |
| Lantheus Holdings Inc LNTH | 30 | Normal | Healthcare | United States | 5 / 6 | $6.6B |
| Ypsomed Holding AG OWX | 28 | Normal | Healthcare | Switzerland | 5 / 6 | $6.5B |
| Alibaba Health Information Technology Limited TWY | 48 | Elevated | Healthcare | Hong Kong | 5 / 6 | $6.4B |
| Mirum Pharmaceuticals Inc MIRM | 44 | Elevated | Healthcare | United States | 4 / 6 | $6.3B |
| H Lundbeck A/S HLUN-B | 31 | Normal | Healthcare | Denmark | 3 / 6 | $6.3B |
| Centessa Pharmaceuticals plc CNTA | 73 | Stretched | Healthcare | United Kingdom | 4 / 6 | $6.3B |
| Travere Therapeutics Inc TVTX | 55 | Elevated | Healthcare | United States | 4 / 6 | $6.2B |
| Bausch + Lomb Corp BLCO | 66 | Stretched | Healthcare | Canada | 4 / 6 | $6.2B |
| H Lundbeck A/S HLUN-A | 31 | Normal | Healthcare | Denmark | 3 / 6 | $6.2B |
| Sinopharm Group Co. Ltd X2S | 51 | Elevated | Healthcare | China | 5 / 6 | $6.2B |
| Cochlear Limited OC5 | 41 | Elevated | Healthcare | Australia | 4 / 6 | $6.2B |
| SINOPHARM GROUP 1/5/O.N. X2S1 | 52 | Elevated | Healthcare | China | 5 / 6 | $6.2B |
| Kiniksa Pharmaceuticals International plc. - Class A KNSA | 24 | Normal | Healthcare | United Kingdom | 4 / 6 | $6.1B |
| Liquidia Corp LQDA | 51 | Elevated | Healthcare | United States | 5 / 6 | $6.1B |
| Teleflex Incorporated TFX | 68 | Stretched | Healthcare | United States | 5 / 6 | $6.0B |
| ConvaTec Group PLC 2CV | 43 | Elevated | Healthcare | United Kingdom | 5 / 6 | $6.0B |
| Radnet Inc RDNT | 45 | Elevated | Healthcare | United States | 5 / 6 | $6.0B |
| Stevanato Group Spa STVN | 45 | Elevated | Healthcare | Italy | 5 / 6 | $5.9B |
| Xenon Pharmaceuticals Inc XENE | 64 | Stretched | Healthcare | Canada | 4 / 6 | $5.8B |
| PTC Therapeutics Inc PTCT | 15 | Contained | Healthcare | United States | 4 / 6 | $5.8B |
| Dianthus Therapeutics Inc DNTH | 67 | Stretched | Healthcare | United States | 5 / 6 | $5.8B |
By sector
Industrials 1,536Technology 1,292Healthcare 1,214Consumer Cyclical 1,116Basic Materials 577Communication Services 565Real Estate 552Consumer Defensive 536Energy 356Utilities 232
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.